Skip to main content

Table 4 Clinical characteristics of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

ID Gender Age Epistaxis before SarsCov-2 infection Epistaxis profile during infection Visceral involvement (AVMs) Hb deficit level Covid-19 symptoms/manifestations Non-HHT co-morbidities
4 F 41 Yes Worsening No Mild GOS Osteoporosis, Autoimmune Thyroiditis
20 M 46 Yes Unchanged No Mild Asymptomatic Hypert., Hemodialysis, Chronic Kidney Disease
22 M 44 Yes Unchanged No Intermediate Pn, F, C,T, R, D, ST, GOSa  
24 M 57 Yes Unchanged No   Pn, F, C, Rb  
34 F 38 Yes Worsening No   F, R, M,T, ST  
39 F 35 Yes Worsening P, H Mild F, H, M,T, D Asthma
49 M 41 Yes Unchanged No Mild F, C,H, M,T,GOS  
66 M 49 Yes Unchanged No   Pn, F, R Hypert
119 M 65 Yes Unchanged P, H, GI Mild Pn, F, C, T  
  1. Visceral Involvement: Organ displaying HHT-related Arterio-Venous Malformations (AVMs). P pulmonary arterio-venous malformations, H hepatic arterio-venous malformations, GI gastrointestinal arterio-venous malformations, Pn pneumonia, F fever, C coughing, H headache, R respiratory dyspnea, M muscular pain, T sense of tiredness/fatigue, D diarrhoea, ST sore throat, GOS gustative/olfactory sensory impairment. Hb level: Mild (Hb > 12 gr/dl), Intermediate (10–12 gr/dl), Severe 7–10 gr/dl), Very Severe (< 7 gr/dl)
  2. aNeeded Hospitalization and Intensive care (Invasive Ventilation)
  3. bNeeded Hospitalization and Intensive care (Non-Invasive Ventilation)